{
    "nctId": "NCT00053911",
    "briefTitle": "Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer",
    "officialTitle": "Randomized And Multicentric Phase III Study Evaluating The Benefit By Using A Chemotherapy With FEC 100 And Docetaxel In Non Metastatic Breast Cancer Which Has Relapsed After A Conservative Surgery",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": "N/A",
    "primaryOutcomeMeasure": "Evaluation of the disease free survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * No contralateral breast cancer\n* Local tumor recurrence more than 6 months after conservative surgery\n* Complete or conservative resection of the recurrent tumor NOTE: Initial complete surgical resection not allowed\n* No local inflammatory disease or disease that is not amenable to complete surgical resection\n* No positive axillary lymph nodes\n* No distant metastases, including subclavicular lymph nodes\n* Hormone receptor status:\n\n  * Hormone receptor status known\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 to 65\n\nSex\n\n* Female\n\nMenopausal status\n\n* Menopausal status known\n\nPerformance status\n\n* ECOG 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Neutrophil count at least 2,000/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n\nHepatic\n\n* Bilirubin no greater than upper limit of normal (ULN)\n* Transaminases no greater than 1.5 times ULN\n* Alkaline phosphatase no greater than 2.5 times ULN\n* No chronic hepatitis B\n* No active hepatitis C\n\nRenal\n\n* Not specified\n\nCardiovascular\n\n* Cardiac function normal by echocardiogram or isotopes\n\nOther\n\n* No contraindications to anthracyclines such as any of the following:\n\n  * Prior doxorubicin over 300 mg/m\\^2\n  * Prior epirubicin over 600 mg/m\\^2\n  * Prior mitoxantrone over 90 mg/m\\^2\n* No other invasive malignancy\n* No chronic somatic or psychiatric condition that would preclude study participation\n* No familial, social, geographic, or psychological reason that would preclude study participation\n* Not pregnant\n* Fertile patients must use effective contraception\n* HIV negative\n* CA 153 no greater than 2 times ULN\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* See Patient Characteristics-Other\n* No prior neoadjuvant chemotherapy\n\nEndocrine therapy\n\n* No prior neoadjuvant hormonal therapy\n\nRadiotherapy\n\n* No prior neoadjuvant radiotherapy\n\nSurgery\n\n* See Disease Characteristics\n* At least 41 days since prior surgery",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}